Grifols (NASDAQ:GRFS) Shares Gap Up - What's Next?

Key Points

• Grifols, S.A. shares gapped up from $9.63 to $10.06 prior to trading, closing last at $9.98 with a trading volume of 132,787 shares.
• Analysts have varying views on Grifols, with a consensus rating of "Moderate Buy" and a price target of $10.30; institutional investors have also been active, with significant stake increases.
• The company announced a special dividend of $0.1404 paid to investors of record on August 12, with a current dividend payout ratio of 11.97%.

Grifols, S.A. (NASDAQ:GRFS - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $9.63, but opened at $10.06. Grifols shares last traded at $9.98, with a volume of 132,787 shares trading hands.

Analysts Set New Price Targets

GRFS has been the subject of a number of research reports. Wall Street Zen upgraded Grifols from a "buy" rating to a "strong-buy" rating in a report on Monday, July 7th. JPMorgan Chase & Co. increased their price target on Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a research report on Tuesday, June 17th. Zacks Research raised Grifols to a "hold" rating in a research report on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Grifols in a research note on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $10.30.

Grifols Stock Down 0.8%

The business has a 50-day moving average price of $10.13 and a two-hundred day moving average price of $8.69. The company has a quick ratio of 0.95, a current ratio of 2.64 and a debt-to-equity ratio of 1.20. The firm has a market cap of $6.70 billion, a PE ratio of 8.32, a price-to-earnings-growth ratio of 0.33 and a beta of 0.64.

Grifols Announces Dividend

The company also recently disclosed a special dividend, which was paid on Wednesday, August 20th. Stockholders of record on Tuesday, August 12th were given a dividend of $0.1404 per share. The ex-dividend date of this dividend was Tuesday, August 12th. Grifols's payout ratio is 11.97%.

Hedge Funds Weigh In On Grifols

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Credit Industriel ET Commercial acquired a new position in shares of Grifols during the fourth quarter worth about $4,537,000. Jane Street Group LLC grew its position in shares of Grifols by 87.9% in the fourth quarter. Jane Street Group LLC now owns 76,729 shares of the biotechnology company's stock valued at $571,000 after purchasing an additional 35,901 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of Grifols by 9.2% in the fourth quarter. BNP Paribas Financial Markets now owns 65,082 shares of the biotechnology company's stock valued at $484,000 after purchasing an additional 5,505 shares during the last quarter. Quantinno Capital Management LP grew its position in shares of Grifols by 22.7% in the fourth quarter. Quantinno Capital Management LP now owns 128,303 shares of the biotechnology company's stock valued at $955,000 after purchasing an additional 23,758 shares during the last quarter. Finally, Tidal Investments LLC grew its position in shares of Grifols by 49.3% in the fourth quarter. Tidal Investments LLC now owns 24,638 shares of the biotechnology company's stock valued at $183,000 after purchasing an additional 8,138 shares during the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.